Regeneron stock pre-market at EUR 710.60
Published on 10/16/2026 at 08:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults and calendar
- Regeneron is scheduled to report third-quarter 2026 results on October 30, 2026.
- Regeneron stock was at EUR 710.60 at 7:58 a.m. CEST on October 16, 2026, according to Lang & Schwarz.
- The OPTIMA extension enrolled 63 adults and evaluated Pasatru through 84 weeks.
Regeneron stock was at EUR 710.60 pre-market at 7:58 a.m. CEST on October 16, 2026, according to Lang & Schwarz.
Pre-market trading
The price was recorded before the Xetra session. The real-time quote of Regeneron stock provides continuously updated market information.
Market context: Market report S&P 500.
Upcoming results and trial data
Regeneron said in a company release dated September 24, 2026, that it will publish its third-quarter 2026 financial and operating results on October 30, 2026, before U.S. financial markets open. The company said the conference call and webcast will begin at 8:30 a.m. Eastern Time.
In an October 12, 2026 GlobeNewswire release, Regeneron reported 84-week results from the Phase 3 OPTIMA trial of Pasatru in adults with fibrodysplasia ossificans progressiva. The trial enrolled 63 adults, with 58 completing the extension phase to at least 84 weeks. From week 56 to week 84, no new heterotopic ossification lesions were observed for Pasatru compared with nine for placebo.
